Literature DB >> 17241784

Progressive myopathy with up-regulation of MHC-I associated with statin therapy.

Merrilee Needham1, Victoria Fabian, Wally Knezevic, Peter Panegyres, Paul Zilko, Frank L Mastaglia.   

Abstract

Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug. What is less well known is a phenomenon whereby statins may induce a myopathy, which persists or may progress after stopping the drug. We investigated the muscle pathology in 8 such cases. All had myofibre necrosis but only 3 had an inflammatory infiltrate. In all cases there was diffuse or multifocal up-regulation of MHC-I expression even in non-necrotic fibres. Progressive improvement occurred in 7 cases after commencement of prednisolone and methotrexate, and in one case spontaneously. These observations suggest that statins may initiate an immune-mediated myopathy that persists after withdrawal of the drug and responds to immunosuppressive therapy. The mechanism of this myopathy is uncertain but may involve the induction by statins of an endoplasmic reticulum stress response with associated up-regulation of MHC-I expression and antigen presentation by muscle fibres.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17241784     DOI: 10.1016/j.nmd.2006.10.007

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  62 in total

1.  Safety of statin drugs in patients with dyslipidemia and stable systemic autoimmune myopathies.

Authors:  Isabela Bruna Pires Borges; Samuel Katsuyuki Shinjo
Journal:  Rheumatol Int       Date:  2018-12-05       Impact factor: 2.631

2.  A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy.

Authors:  Lisa Christopher-Stine; Livia A Casciola-Rosen; Grace Hong; Tae Chung; Andrea M Corse; Andrew L Mammen
Journal:  Arthritis Rheum       Date:  2010-09

3.  Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy.

Authors:  Andrew L Mammen; Daniel Gaudet; Diane Brisson; Lisa Christopher-Stine; Thomas E Lloyd; Mary S Leffell; Andrea A Zachary
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-08       Impact factor: 4.794

4.  Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase.

Authors:  Dirk Essers; Martina Schäublin; Gerd A Kullak-Ublick; Stefan Weiler
Journal:  Eur J Clin Pharmacol       Date:  2018-11-15       Impact factor: 2.953

Review 5.  Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management.

Authors:  Pari Basharat; Lisa Christopher-Stine
Journal:  Curr Rheumatol Rep       Date:  2015-12       Impact factor: 4.592

Review 6.  Mechanisms and assessment of statin-related muscular adverse effects.

Authors:  Dirk Moßhammer; Elke Schaeffeler; Matthias Schwab; Klaus Mörike
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

7.  Complement membrane attack complex is related with immune-mediated necrotizing myopathy.

Authors:  Lu Cong; Chuan-Qiang Pu; Qiang Shi; Qian Wang; Xiang-Hui Lu
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

8.  Mystery case: a 63-year-old man with progressive proximal pain and weakness.

Authors:  Patricia D Scripko; Anthony A Amato; Alberto Puig
Journal:  Neurology       Date:  2014-01-28       Impact factor: 9.910

9.  Adaptive immune response to therapy in hmgcr autoantibody myopathy.

Authors:  John S Yi; Melissa A Russo; Kent J Weinhold; Jeffrey T Guptill
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

Review 10.  Is statin-induced myositis part of the polymyositis disease spectrum?

Authors:  Jemima Albayda; Andrew L Mammen
Journal:  Curr Rheumatol Rep       Date:  2014-08       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.